Dingke Medical announced today that it has completed 60 million B rounds of financing. This round of financing was led by Qiming Venture Capital and Heyu No.1 jointly invested. It is reported that this is another round of financing after Dingke Medical's financing of 20 million yuan last year. This round of financing will be used to promote the clinical trial and registration of cardiovascular intervention consumables, expand the research and development pipeline layout of other vascular intervention products, and gradually build commercial team. In addition, Weng Yulin, the founder of Dingke Medical, said that they are based on cardiovascular interventions and also lay out other potential markets that are about to break out, such as peripheral blood vessels. Cardiovascular disease is the number one cause of death worldwide. The number of people dying from cardiovascular disease each year in the world is as high as 15 million, accounting for 20-30% of the total number of deaths worldwide. In China, with the development of social economy, especially the acceleration of population aging process, the trend of cardiovascular disease risk factors has become more and more obvious, and the number of cases continues to grow, and will continue to grow rapidly in the next 10 years. At present, surgical replacement, bypass grafting and stent implantation are the main treatments. Established in 2015, Dingke Medical is a company specializing in R&D and production of vascular interventional medical treatment products. It aims to enter the market in the next 10 years and continuously introduces domestically replaced medical devices. At present, cardiovascular interventional accessories such as PTCA balloon have entered the registration stage, and the coronary drug balloon has been in clinical trials. For the introduction of domestically produced alternative medical devices, Weng Yulin said that from the perspective of medical insurance control fees, domestic substitution is the trend. And in theory, Dingke will have a late-comer advantage over foreign medical companies. Foreign companies have done 1 from 0. Based on foreign samples and data, Dingke has made in-depth understanding of the needs of China, doctors and patients to improve and improve performance and experience. In addition, in terms of product development and launch, Dingke Medical and other companies' individual products are successively developed and re-launched. They tend to reserve a whole set of products from the beginning, so as to avoid the clinical small products and get the license, and to break the commercial and large-scale production capacity. When the core products are listed around 2020, business coverage can be smoother. In terms of company team, founder CEO Weng Yulin was the technical backbone of Biosensors (Singapore Parkson Group). He has launched several star products in Europe, Japan and China, with a total of 14 employees. Weng Yulin said that from a micro level, a small number of teams can give high-income employees as much as possible, and at the same time let them take on more responsibilities, can quickly learn to grow, and work more fulfilling. From a macro level, reducing the company's internal friction, the "bullet" hit the pain, really boost the company's development. Nowadays, in the venture capital circle, everyone is shouting capital winter, and investment tends to be cautious. Weng Yulin said that Dingke's current round of financing was smooth, and the team's contribution was recognized by the capital market. At present, the company's research products are progressing smoothly. The addition of Qiming Venture Capital and Heyu No.1 will greatly promote the development of the company and provide financial support for the subsequent research products. Dingke will bring the products to the market as soon as possible to make the domestic The patient benefits early. For the investment of Dingke Medical, Hu Xubo, the managing partner of Qiming Ventures, said that Dingke Medical's founding team has many years of cardiovascular equipment industry experience, and has successful development experience in international intervention products and in-depth understanding of the domestic clinical market. Be optimistic about the reasons for Dingke. The Improved Digestion Extract category of Shaanxi Changsheng Industrial Co., Ltd, offers a selection of plant extracts designed to promote the optimal functioning of the digestive system. This assortment is designed for those seeking comfortable digestion and overall health. Improved Digestion Extract,Lotus Leaf Extract,Bulk Passionflower Extract,Green Coffee Beans Extract Shaanxi Changsheng Industrial Co., Ltd. , https://www.sxcsmalehealth.com
Our Improved Digestion Extracts blend ancient herbal wisdom with modern science to provide a natural and effective way to support your digestive system. For example, Passion Fruit Extract, Lotus Leaf Extract, Senna Leaves Extract Powder, Green Coffee Bean Extract, Hawthorn Berry Extract Flavanone Powder, and more, these extracts may help to balance stomach acid, promote intestinal health, and provide overall comfort. Whether you're looking to address digestive discomfort, improve the absorption of your diet, or simply pursue a healthier lifestyle, this assortment has the ideal solution for you.